Navigation Links
BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program
Date:6/1/2009

BCBSNC customers saved at least $15 million in out-of-pocket costs since January; 2.4 million generic prescriptions filled with no copay; Customers have until June 30,2009 to save with the generic copay waiver program

Chapel Hill, NC (Vocus) June 1, 2009 -- Blue Cross and Blue Shield of North Carolina (BCBSNC) is helping customers save money and stay on their medications with the generic copay waiver program. BCBSNC customers saved at least $15 million in out-of-pocket expenses since the program started January 1, 2009. The program will run until June 30.

The generic copay waiver program is in effect until the end of the year for eligible customers taking generics to treat chronic conditions such as hypertension, congestive heart failure, high cholesterol and diabetes.

"In this tough economy, the generic copay waiver program allows BCBSNC customers to control out-of-pocket costs by using generic drugs," says Ron Smith, PharmD, BCBSNC vice president of employer health and corporate pharmacy. "The savings our customers see through the program reaffirms that the generic copay waiver program helps people to better manage their health and not be forced to choose between medication and paying their bills."

The 2009 generic copay waiver program applies to nearly 1 million BCBSNC customers and eliminates customer copays for covered generic drugs. Eligible BCBSNC customers include:    

 
  • Blue Advantage customers (once they meet their annual prescription deductible, if applicable).
  • Medicare Supplement customers who have prescription coverage on their policies (once they meet their annual prescription deductible, if applicable).
  • Members of insured employer groups (if their employer group has pharmacy benefits through BCBSNC).
  • Members of self-funded employer groups (if their employer group has pharmacy benefits through BCBSNC and has chosen to participate in the program).

Generic drugs are equivalent to corresponding brand name drugs in active ingredients, dosage, strength, safety and performance, but they cost a fraction of their brand name counterparts. Since prescription drug costs are a key driver of rising medical costs, the long-term increased use of generics also impacts future premiums for the benefit to BCBSNC customers.

With or without the copay waiver, generic medications cost less out-of-pocket than brand-name medications. Generic copay waiver programs increase those savings and highlight the benefits of generic medications.

About BCBSNC:
Blue Cross and Blue Shield of North Carolina is a leader in delivering innovative health care products, services and information to more than 3.7 million members, including approximately 900,000 served on behalf of other Blue Plans. For 76 years, the company has served its customers by offering health insurance at a competitive price and has served the people of North Carolina through support of community organizations, programs and events that promote good health. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association. Access BCBSNC online at www.bcbsnc.com.

###

Read the full story at http://www.prweb.com/releases/blue_cross_blue_shield/free_generics/prweb2463464.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. BCBSNC Makes Electronic Prescribing Available Statewide
2. BCBSNC Helps Customers Fight Recession With Free Generics
3. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
4. Texas Aviation Services: Over 20 Years of Creating Flying Emergency Rooms for Airborne EMS Customers in US and Latin America
5. New Technology at Unitrin Direct Gives Customers an Alternative to Waiting
6. Verizon Introduces Broadband Video Call Center Link for Deaf or Hard-of-Hearing Customers in Mid-Atlantic Region
7. Stop & Shop Alerts Customers to Product Advisory by ConAgra Foods
8. Giant Food Alerts Customers to Product Recall by ConAgra Foods
9. Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinovas Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements
10. UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires
11. RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... understand each Medicare Advantage member’s risk, identify any gaps-in-coding, as well as ... helps transform the HCC Risk Adjustment process from a typical fragmented process ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its steady ... Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission Hills ... liability and other personal injury cases. These injuries have a major impact on ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Using the ... leads utilizing a simple online checklist. Over a period of just 24 months, thousands ... assistance of an online checklist called T.A.D. , “The internet is not getting quieter. ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Centers for ... help small practices in Delaware, New Jersey, Pennsylvania and West Virginia prepare for ... and CHIP Reauthorization Act of 2015 (MACRA). , This technical assistance, authorized ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , February 23, 2017 ... market: the Berlin office was ... Magdalena Kritikos . The portfolio includes Entocort ® ... for the treatment of ulcerative colitis, and VistaPrep ® ... solutions, the Swiss specialty pharmaceutical company focused on the ...
(Date:2/23/2017)... 2017 MabVax Therapeutics Holdings, Inc ... company, announces that it has received notice from ... the initiation a Phase I clinical trial with ... MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel ... initiate the phase I clinical trial in patients ...
(Date:2/23/2017)... 23, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ... oncology and dermatology biopharmaceutical company, today announced that it ... Rodrigues as special advisers to the Company,s Board ... the board on financial and corporate strategy. ... commitment of up to $2.5 million from Eric ...
Breaking Medicine Technology: